All the news Showing 8 of 228 articles from: TherapiesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Persistence of very low levels of virus increase risk of relapse after hepatitis C therapy Michael Carter / 04 November 2011 The persistence of a low viral load during the first twelve weeks of hepatitis C therapy is associated with an increased risk of relapse after the completion of treatment, investigators report in ... Hepatitis C drug boceprevir achieves 70% viral suppression rate in HIV co-infected people within 24 weeks Gus Cairns / 22 October 2011 Interim results presented at the Infectious Diseases Society of America (IDSA) conference yesterday show that 70.5% of 98 patients with HIV and hepatitis C who took the hepatitis C protease inhibitor (PI) drug ... New anti-hepatitis C drug BMS-790052 does well in Phase IIa study Michael Carter / 20 September 2011 Up to 83% of individuals with chronic hepatitis C virus achieved a sustained virological response after receiving the investigational drug BMS-790052 in combination with pegylated interferon and ribavirin, results of a study presented ... Boceprevir response and resistance differs according to HCV genotype 1 subtype Liz Highleyman / 28 July 2011 People with hepatitis C virus (HCV) genotype 1b respond better to boceprevir and are less likely to develop drug resistance than those with genotype 1a, according to study findings reported ... US approval for hepatitis C drug telaprevir Keith Alcorn / 23 May 2011 The US Food and Drug Administration has approved a new hepatitis C drug telaprevir (Incivek), the agency announced today. Telaprevir is a direct-acting antiviral drug (an HCV protease inhibitor), licensed for use in combination ... European approval recommended for hepatitis C drug boceprevir Keith Alcorn / 23 May 2011 The European Medicines Agency has recommended marketing approval for Merck’s hepatitis C protease inhibitor boceprevir (Victrelis), the agency announced on May 20th. Boceprevir is the first direct-acting antiviral agent for hepatitis C to be ... New hepatitis C drugs pose many questions Keith Alcorn / 08 April 2011 Even before new hepatitis C drugs come to market later this year, the vast array of hepatitis C antivirals currently in clinical trials is opening up new horizons for treatment of hepatitis ... Telaprevir works well for people with HIV/HCV co-infection Liz Highleyman / 02 March 2011 The experimental hepatitis C virus (HCV) protease inhibitor telaprevir, used with pegylated interferon plus ribavirin, produced good virological response in the first study of HIV/HCV co-infected individuals, according to interim data presented on Wednesday ... ← Prev1...1920212223Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Transmission and prevention Diagnosis and monitoring Disease course and symptoms HCV and coinfections Living with HCV Treatment issues Side effects Therapies Liver transplants Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive